Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Pilot Study Evaluating Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis

NCT03867097 is registered in ClinicalTrials.gov with Civi Biopharma, Inc. as lead sponsor.

NCT NCT03867097
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03867097 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Pilot Study Evaluating Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis
Lead sponsor
Civi Biopharma, Inc.
Phase
Phase 2
Overall status
Completed
Start date
March 7, 2019
Completion date
August 6, 2019
Enrollment
34 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

raynaud phenomenon secondary to systemic sclerosis